Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
Status:
Completed
Trial end date:
2017-01-06
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the rate of complete remission/complete remission with
partial hematological recovery (CRh*) in adults with relapsed/refractory Philadelphia
chromosome positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL) who receive
blinatumomab.